Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:40 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 1,494 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Intervention 2 - Placebo Clear all

Conditions: Alcohol Use Disorder (AUD), PTSD
Interventions: Psilocybin 25 mg, Maltodextrin (Placebo); Drug
Lead sponsor: Nathan Brashares Sackett; Other
Eligibility: 21 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Human Immunodeficiency Virus
Interventions: Baricitinib 2 MG Oral Tablet, Placebo; Drug
Lead sponsor: William Tyor; Other
Eligibility: 18 Years to 65 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Obstructive Sleep Apnea
Interventions: Placebo, Acetazolamide, Trazodone, Atomoxetine and eszopiclone; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 21 Years to 70 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Polycystic Ovary Syndrome
Interventions: Metformin, Oral Contraceptive Pill, Lifestyle Management Program, Quality of Life Questionnaire, Oral Glucose Tolerance Test, Blood work, Abdominal Ultra Sound, Dual-energy x-ray absorptiometry (DEXA scan), placebo; Drug · Behavioral · Procedure
Lead sponsor: University of Rochester; Other
Eligibility: 12 Years to 18 Years · Female only
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Mild Cognitive Impairment
Interventions: Circadian-Effective Light, Rhythmic Light, Placebo Light, Placebo Rhythmic Light; Device
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 55 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Menands, New York • New York, New York

Conditions: Binge-Eating Disorder, Circadian Rhythm Disorders
Interventions: Melatonin (3hrs before DLMO), Placebo (3hrs before DLMO), Morning light version 1, Morning light version 2; Dietary Supplement · Device
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years to 50 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Mason, Ohio

Conditions: Stress, Sleep, Craving, Well Being
Interventions: Ashwagandha, Placebo; Dietary Supplement · Other
Lead sponsor: University of Colorado, Colorado Springs; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Colorado Springs, Colorado

Conditions: Coronavirus, Covid19
Interventions: bamlanivimab 7000mg, BRII-196+BRII-198, AZD7442 (IV), AZD7442 (IM), SNG001, Camostat, BMS-986414 + BMS-986413, SAB-185 (3,840 Units/kg), SAB-185 (10,240 Units/kg), CASIRIVIMAB + IMDEVIMAB, Placebo for Bamlanivimab 7000mg, Placebo for Bamlanivimab 700mg, Placebo for BRII-196+BRII-198, Placebo for SNG001, Placebo for Camostat, Placebo for SAB-185 (low dose), Placebo for BMS-986414 + BMS-986413, Placebo for AZD7442 (IV), Placebo for AZD7442 (IM), Placebo for SAB-185 (high dose), bamlanivimab 700mg; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 4,044 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 207
States / cities: Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 143 more

Conditions: Hidradenitis Suppurativa
Interventions: Ritlecitinib, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 30
States / cities: Hot Springs, Arkansas • Fountain Valley, California • Northridge, California + 22 more

Conditions: Myotonia, Non-Dystrophic Myotonia
Interventions: Mexiletine, Placebo; Drug
Lead sponsor: Richard Barohn, MD; Other
Eligibility: 16 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 4
States / cities: Kansas City, Kansas • Boston, Massachusetts • Rochester, New York + 1 more

Conditions: COVID, COVID-19, Corona Virus Infection
Interventions: Sarilumab 200 MG/1.14 ML Subcutaneous Solution, Placebo; Drug
Lead sponsor: BayCare Health System; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 3
States / cities: Clearwater, Florida • St. Petersburg, Florida • Tampa, Florida

Conditions: Fecal Incontinence
Interventions: Loperamide, Placebo, Anal exercises with biofeedback, Usual Care; Drug · Behavioral
Lead sponsor: NICHD Pelvic Floor Disorders Network; Network
Eligibility: 18 Years and older · Female only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 9
States / cities: Birmingham, Alabama • La Jolla, California • San Diego, California + 6 more

Conditions: Graves' Disease
Interventions: Levothyroxine, Placebo; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 70 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Pediatric Obesity
Interventions: Lifestyle intervention and carotenoid supplements, Lifestyle intervention and placebo; Other
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 8 Years to 11 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Heart Failure, Congestive Heart Failure
Interventions: Isosorbide Dinitrate, Isosorbide Dinitrate + Hydralazine, Placebo; Drug
Lead sponsor: Corporal Michael J. Crescenz VA Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Exercise Induced Fatigue
Interventions: Palmar Cooling, Placebo Palmar Cooling; Device
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 18 Years to 30 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Bloodloss, Surgical Procedures, Operative
Interventions: ecallantide, placebo; Drug
Lead sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 85 Years
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 21
States / cities: Birmingham, Alabama • Montgomery, Alabama • Aurora, Colorado + 14 more

Conditions: Muscle Soreness
Interventions: Cannabidiol cream, Placebo cream; Other
Lead sponsor: Joseph Pastina; Other
Eligibility: 18 Years to 45 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Lexington, Kentucky

Conditions: Schizophrenia
Interventions: Minocycline, Placebo; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 65 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Catonsville, Maryland

Conditions: Schizophrenia, Schizophreniform Disorder
Interventions: Citalopram, Placebo, Psychoeducation, Cognitive Behavioral Therapy (CBT), Functional Magnetic Resonance Imaging (fMRI); Drug · Behavioral · Radiation
Lead sponsor: NYU Langone Health; Other
Eligibility: 16 Years to 40 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Pancreatic Cysts
Interventions: Ciprofloxacin, Placebo (for ciprofloxacin); Drug · Other
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years to 90 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: HCC
Interventions: Sorafenib, VT-122 (propranolol plus etodolac), Placebo; Drug
Lead sponsor: Vicus Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 10
States / cities: Berkeley, California • Atlanta, Georgia • New Brunswick, New Jersey + 6 more

Conditions: Acupuncture, Hip Surgery, Opioid Use
Interventions: Auricular Trauma Protocol (ATP) Acupuncture, No Acupuncture Group; Device · Other
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years to 80 Years
Enrollment: 484 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Malaria
Interventions: PfRAS, Placebo, Challenge; Biological · Other
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 50 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

PsiloStudy: Psilocybin With Psychological Support (Psi-PS) for Military Veterans and First Responders With Co-occurring PTSD & Alcohol Use Disorder (AUD)

Baricitinib for Reduction of HIV - CNS

Rescue Pharmacotherapy for OSA

Impact of Metformin in Teens With Polycystic Ovary Syndrome (PCOS) on Oral Contraceptive Therapy

Phase 2 - Rhythmic Light Therapy for Alzheimer's Disease Patients

The Role of the Circadian System in Binge Eating Disorder

The Impact of Ashwagandha on Perceived Stress, Sleep and Food Cravings in College Students

ACTIV-2: A Study for Outpatients With COVID-19

A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.

Effectiveness of Mexiletine for Treating People With Non-Dystrophic Myotonia

Subcutaneous Sarilumab vs Placebo in Hospitalized Patients With Respiratory Distress Caused by COVID 19

Controlling Anal Incontinence by Performing Anal Exercises With Biofeedback or Loperamide (CAPABLe)

Early Levothyroxine Post Radioactive Iodine

Family-based Lifestyle Intervention Program and Carotenoid Supplementation for Children With Obesity

Vasodilator Therapy for Heart Failure and Preserved Ejection Fraction

The Effects of Palmar Cooling on Repeated Sprinting Ability

A Dose-ranging Safety and Efficacy Study of Ecallantide to Reduce Surgical Blood Loss Volume

Topical CBD's Effects on Soreness and Performance

Adjunctive Minocycline in Clozapine Treated Schizophrenia Patients

DECIFER: Depression and Citalopram In First Episode Recovery

A Pilot Study on the Use of Prophylactic Antibiotics for EUS-guided Pancreatic Cyst Aspiration

Study of Sorafenib With or Without VT-122 in Patients With Hepatocellular Carcinoma (HCC)

Incorporating Acupuncture Into ERAS for Ambulatory Total Hip Replacement (THR) Surgery

Immunization Via Mosquito Bite With Radiation-attenuated Sporozoites